266 related articles for article (PubMed ID: 21156284)
1. β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells.
Yeung J; Esposito MT; Gandillet A; Zeisig BB; Griessinger E; Bonnet D; So CW
Cancer Cell; 2010 Dec; 18(6):606-18. PubMed ID: 21156284
[TBL] [Abstract][Full Text] [Related]
2. Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway.
Fung TK; Gandillet A; So CW
Curr Opin Hematol; 2012 Jul; 19(4):280-6. PubMed ID: 22525581
[TBL] [Abstract][Full Text] [Related]
3. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
[TBL] [Abstract][Full Text] [Related]
4. Overcoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cells.
Perry JM; Tao F; Roy A; Lin T; He XC; Chen S; Lu X; Nemechek J; Ruan L; Yu X; Dukes D; Moran A; Pace J; Schroeder K; Zhao M; Venkatraman A; Qian P; Li Z; Hembree M; Paulson A; He Z; Xu D; Tran TH; Deshmukh P; Nguyen CT; Kasi RM; Ryan R; Broward M; Ding S; Guest E; August K; Gamis AS; Godwin A; Sittampalam GS; Weir SJ; Li L
Nat Cell Biol; 2020 Jun; 22(6):689-700. PubMed ID: 32313104
[TBL] [Abstract][Full Text] [Related]
5. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
6. Phosphoinositide-dependent kinase 1 regulates leukemia stem cell maintenance in MLL-AF9-induced murine acute myeloid leukemia.
Hu T; Li C; Zhang Y; Wang L; Peng L; Cheng H; Wang W; Chu Y; Xu M; Cheng T; Yuan W
Biochem Biophys Res Commun; 2015 Apr; 459(4):692-8. PubMed ID: 25769952
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional memory of cells of origin overrides β-catenin requirement of MLL cancer stem cells.
Siriboonpiputtana T; Zeisig BB; Zarowiecki M; Fung TK; Mallardo M; Tsai CT; Lau PNI; Hoang QC; Veiga P; Barnes J; Lynn C; Wilson A; Lenhard B; So CWE
EMBO J; 2017 Nov; 36(21):3139-3155. PubMed ID: 28978671
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
9. FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML.
Sheng Y; Yu C; Liu Y; Hu C; Ma R; Lu X; Ji P; Chen J; Mizukawa B; Huang Y; Licht JD; Qian Z
Nat Commun; 2020 Feb; 11(1):928. PubMed ID: 32066721
[TBL] [Abstract][Full Text] [Related]
10. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
11. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
Wong P; Iwasaki M; Somervaille TC; So CW; Cleary ML
Genes Dev; 2007 Nov; 21(21):2762-74. PubMed ID: 17942707
[TBL] [Abstract][Full Text] [Related]
12. The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML.
Wang Y; Krivtsov AV; Sinha AU; North TE; Goessling W; Feng Z; Zon LI; Armstrong SA
Science; 2010 Mar; 327(5973):1650-3. PubMed ID: 20339075
[TBL] [Abstract][Full Text] [Related]
13. Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.
Aikawa Y; Yamagata K; Katsumoto T; Shima Y; Shino M; Stanley ER; Cleary ML; Akashi K; Tenen DG; Kitabayashi I
Cancer Sci; 2015 Mar; 106(3):227-36. PubMed ID: 25529853
[TBL] [Abstract][Full Text] [Related]
14. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression.
Wong P; Iwasaki M; Somervaille TC; Ficara F; Carico C; Arnold C; Chen CZ; Cleary ML
Cancer Res; 2010 May; 70(9):3833-42. PubMed ID: 20406979
[TBL] [Abstract][Full Text] [Related]
15. Amide-linked local anesthetics preferentially target leukemia stem cell through inhibition of Wnt/β-catenin.
Ni J; Xie T; Xiao M; Xiang W; Wang L
Biochem Biophys Res Commun; 2018 Sep; 503(2):956-962. PubMed ID: 29932919
[TBL] [Abstract][Full Text] [Related]
16. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
17. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/β-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia.
Jin B; Wang C; Li J; Du X; Ding K; Pan J
Clin Cancer Res; 2017 Feb; 23(3):789-803. PubMed ID: 27492973
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy.
Wang Z; Smith KS; Murphy M; Piloto O; Somervaille TC; Cleary ML
Nature; 2008 Oct; 455(7217):1205-9. PubMed ID: 18806775
[TBL] [Abstract][Full Text] [Related]
19. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
20. CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.
Iwasaki M; Liedtke M; Gentles AJ; Cleary ML
Cell Stem Cell; 2015 Oct; 17(4):412-21. PubMed ID: 26387756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
